RPRML inhibitors are a class of chemical compounds that target and inhibit the activity of the RPRML (Reprimo-Like) protein. RPRML is a member of the Reprimo family of proteins, which are known for their role in cellular processes such as cell cycle regulation, apoptosis, and response to stress signals. These proteins are typically involved in the maintenance of cellular integrity and the regulation of gene expression under various physiological conditions. Inhibitors of RPRML function by binding to key domains of the protein, often disrupting its ability to interact with other cellular components or signaling pathways. This disruption may affect the protein's ability to modulate transcription factors or regulate downstream molecular cascades, altering cellular responses to environmental or internal signals.
Chemically, RPRML inhibitors are designed to interfere with the conformational changes of the RPRML protein, preventing it from adopting its active form. These inhibitors can exhibit high specificity for RPRML by targeting unique structural motifs or binding pockets within the protein's tertiary structure. Structural biology and computational modeling are often employed to identify regions on RPRML that are susceptible to inhibition, leading to the development of molecules that precisely fit within these sites. Research into RPRML inhibitors typically involves detailed studies of protein-ligand interactions, kinetic profiles, and binding affinities to elucidate how these molecules influence the activity of RPRML at a molecular level. This understanding contributes to the broader field of protein interaction inhibitors, providing insight into how modulation of such proteins can alter intracellular signaling pathways without necessarily affecting related proteins in the same family.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Inhibits a broad spectrum of protein kinases, which can modify signaling pathways that might intersect with RPRML functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can disrupt phosphatidylinositol signaling, potentially altering the activity of proteins associated with RPRML. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Acts as a JNK inhibitor, which can alter stress-responsive signaling pathways and thus potentially modulate RPRML involvement in these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor which can affect inflammatory response pathways potentially involving RPRML. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, which could disrupt signaling pathways that may affect proteins that regulate RPRML. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can influence cell growth and survival pathways, possibly involving RPRML. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog signaling pathway by targeting the Smoothened receptor, potentially affecting downstream proteins related to RPRML. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that could alter MAPK/ERK pathway activity, thus affecting signaling pathways associated with RPRML. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, which can modulate cytoskeleton organization and cell adhesion processes, potentially impacting RPRML if it is associated with these cellular functions. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Disrupts Rac1 activation, which could influence actin cytoskeleton dynamics and potentially any RPRML-related cellular responses. | ||||||